Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis

被引:28
作者
Chan, CT [1 ]
Mardirossian, S [1 ]
Faratro, R [1 ]
Richardson, RMA [1 ]
机构
[1] Toronto Gen Hosp, Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON M5G 2C4, Canada
关键词
nocturnal hemodialysis (NHD); peripheral arterial disease (PAD); calcium phosphate control;
D O I
10.1053/ajkd.2003.50010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A 42-year-old man with end-stage renal disease (ESRD) was referred for conversion to nocturnal hemodialysis (NHD) therapy from conventional hemodialysis (CHD) therapy because of refractory intermittent claudication secondary to peripheral arterial disease (PAD). The patient was initiated on CHD therapy in 1976 and subsequently had undergone two unsuccessful renal transplantations. While on CHD therapy, his clinical course was complicated by worsening vascular and soft-tissue calcification. Extensive dystrophic soft-tissue calcification was noted bilaterally in his hands, lower extremities, and sacral region, requiring surgical excision. Lower-extremity arterial Doppler scans documented vascular calcification and a pronounced decrease in peripheral arterial flow bilaterally. After conversion to NHD therapy (7.5 h/session five times weekly), the patient became symptom free and had significant clinical improvements in (1) hemodynamics, measured by clinic blood pressure and two-dimensional echocardiography, (2) biochemical profile, and (3) a sustained improvement in arterial Doppler flow measured by duplex Doppler ultrasound. We conclude that NHD was able to improve lower-extremity PAD in our patient. Further observational and interventional studies are required to investigate the therapeutic potential of NHD for the treatment of PAD in patients with ESRD.
引用
收藏
页码:225 / 229
页数:5
相关论文
共 20 条
[1]   Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells [J].
Ahmed, S ;
O'Neill, KD ;
Hood, AF ;
Evan, AP ;
Moe, SM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1267-1276
[2]   Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease [J].
Blacher, J ;
Demuth, K ;
Guerin, AP ;
Safar, ME ;
Moatti, N ;
London, GM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (04) :535-541
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]   Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure [J].
Chan, C ;
Floras, JS ;
Miller, JA ;
Pierratos, A .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (08) :1518-1521
[5]   Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis [J].
Chan, CT ;
Floras, JS ;
Miller, JA ;
Richardson, RMA ;
Pierratos, A .
KIDNEY INTERNATIONAL, 2002, 61 (06) :2235-2239
[6]   Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease [J].
Cheng, SWK ;
Ting, ACW ;
Wong, J .
ANNALS OF VASCULAR SURGERY, 1997, 11 (03) :217-223
[7]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[8]   Does calcium kill ESRD patients - the skeptic's perspective [J].
Coladonato, JA ;
Szczech, LA ;
Friedman, EA ;
Owen, WF .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) :229-232
[9]  
Friedman AN, 2002, J AM SOC NEPHROL, V13, P265, DOI 10.1681/ASN.V131265
[10]  
Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131